Aptevo Therapeutics
APVO
9 hedge funds and large institutions have $230K invested in Aptevo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
20% more capital invested
Capital invested by funds: $191K → $230K (+$38.3K)
4.43% more ownership
Funds ownership: 0.12% → 4.55% (+4.4%)
18% less funds holding
Funds holding: 11 → 9 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$134K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$91.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.4K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$534 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$26K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$868 |
| 3 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
-$118 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$66 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$66 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
1
GSA Capital Partners
London,
United Kingdom
| $84K | +$134K | +19,638 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $56.9K | +$91.2K | +13,337 | New |
|
|
VCM
3
Vanguard Capital Management
Malvern,
Pennsylvania
| $54.3K | +$87K | +12,713 | New |
|
|
VFT
4
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $17.7K | +$28.3K | +4,142 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $14.7K | +$22.4K | +3,275 | +1,926% |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $1.53K | – | – | – |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $465 | +$534 | +78 | +252% |
|
8
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $21 | -$7 | -1 | -17% |
|
|
DB
9
Danske Bank
Copenhagen K,
Denmark
| $4 | – | – | – |
|
|
10
Citigroup
New York
| – | -$26K | -2,756 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$868 | -92 | Closed |
|
|
TCM
12
Tradewinds Capital Management
Bellingham,
Washington
| – | -$118 | -13 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$66 | -7 | Closed |
|
|
14
Fidelity Investments
Boston,
Massachusetts
| – | -$66 | -7 | Closed |
|
APVO Hedge Fund Activity: Q1 2026 in Review
9 of the 8,146 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2026, worth a combined $230K — up 20% from $191K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APVO and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $134K. The largest seller was Citigroup, exiting entirely with an estimated $26K sold.
- 9 institutional investors held Aptevo Therapeutics (APVO) as of Q1 2026, down from 11 in Q4 2025.
- Funds reported $230K of Aptevo Therapeutics stock for Q1 2026, up 20% quarter-over-quarter.
- 4 funds opened new Aptevo Therapeutics positions in Q1 2026 and 5 closed out, a net change of -1 holder.
- The largest Aptevo Therapeutics buyer in Q1 2026 was GSA Capital Partners, an estimated $134K added.
- The largest Aptevo Therapeutics seller in Q1 2026 was Citigroup, an estimated $26K sold.
Based on aggregated 13F filings for Q1 2026.